In vivo fluorescence imaging experiments using mice bearing HER2-positive SKBR3 breast cancer xenografts revealed that the site-specifically labeled nanobodies yielded higher tumor-to-background intensity ratios than a construct that had been randomly modified through lysine residues. Here, ERBB2 is linked to breast cancer.